Format

Send to

Choose Destination
JAMA. 2015 Sep 1;314(9):869-70. doi: 10.1001/jama.2015.8405.

Evaluation of Flibanserin: Science and Advocacy at the FDA.

Author information

1
Division of General Internal Medicine and Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
2
Department of Medicine and Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee.
3
Center for Drug Safety and Effectiveness and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland5Section of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.
PMID:
26148201
DOI:
10.1001/jama.2015.8405
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center